MANE
HealthcareVeradermics, Incorporated · Biotechnology · $4B
What is Veradermics, Incorporated?
Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing novel treatments for dermatologic and aesthetic conditions, including hair loss disorders and common skin conditions affecting both adults and children.
Veradermics develops a pipeline of therapeutics targeting unmet needs in dermatology. Its lead program is an oral, non-hormonal treatment for pattern hair loss in men and women. The company also advances a dissolvable microarray patch for wart immunotherapy and separate candidates for alopecia areata, molluscum contagiosum, and atopic dermatitis. Revenue is not yet generated from commercial products, as the company remains in the development stage.
Veradermics was founded in 2019 and is headquartered in New Haven, Connecticut.
- VDPHL01 – oral non-hormonal therapy for chronic pattern hair loss
- VDMN – dissolvable microarray patch for common wart immunotherapy
- VDAA – investigational treatment for alopecia areata
- VDMC – investigational treatment for molluscum contagiosum
Is MANE a Good Stock to Buy?
UQS Score rates MANE as Poor overall, reflecting the early-stage nature of its pipeline and the significant uncertainties that come with pre-commercial biopharmaceutical development.
Among the five pillars, Risk registers as Neutral — the least concerning area — suggesting the company's near-term financial structure is not the most acute pressure point relative to its developmental stage.
Quality, Moat, and Growth all score Weak, while Valuation reads as Elevated, indicating the market may already be pricing in optimistic outcomes that the pipeline has yet to support.
See the complete pillar breakdown and underlying financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MANE pay dividends?
No — Veradermics, Incorporated does not currently pay a dividend.
Veradermics does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Available capital is directed toward research, development, and advancing the pipeline toward regulatory milestones rather than returning cash to shareholders.
When does MANE report earnings?
Veradermics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue, development-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than commercial sales metrics. Investors typically monitor R&D spending trends and any clinical or regulatory updates disclosed alongside financial results.
For the most recent quarter's results and pipeline updates, visit Veradermics' investor relations page directly.
MANE Price History
+60.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
MANE Long-term Outlook
With Growth and Quality both rated Weak, Veradermics faces the challenges common to early-stage biopharma — no commercial revenue, ongoing cash consumption, and binary outcomes tied to clinical trial results. The Elevated Valuation label suggests the current market price may leave limited margin of safety if pipeline milestones are delayed or unsuccessful. The Neutral Risk rating provides some relative comfort on near-term financial structure.
Growth drivers
- Potential clinical advancement of VDPHL01 toward regulatory submission in the large pattern hair loss market
- Microarray patch technology differentiation in dermatology immunotherapy
- Expanding pipeline across multiple underserved dermatologic indications
Key risks
- Clinical trial failure or delays across any pipeline candidate
- Elevated valuation leaving little buffer against negative data readouts
- Ongoing cash burn without commercial revenue to offset development costs
MANE vs Peers
Veradermics operates in a competitive specialty biopharma and dermatology space alongside companies at various stages of development.
Tarsus focuses on eyelid and ocular surface disease, with a commercially approved product already generating revenue — a contrast to Veradermics' fully pre-commercial pipeline.
Enliven is a clinical-stage oncology company whose kinase inhibitor programs differ meaningfully in therapeutic focus from Veradermics' dermatology-centered pipeline.
Structure Therapeutics targets metabolic diseases through GPCR-focused small molecules, representing a different disease area and mechanism compared to Veradermics' dermatologic candidates.
Frequently Asked Questions
What does Veradermics do?
Veradermics is a clinical-stage biopharmaceutical company developing treatments for dermatologic conditions including pattern hair loss, alopecia areata, common warts, molluscum contagiosum, and atopic dermatitis. Its pipeline includes both oral therapies and a novel microarray patch delivery technology. The company has not yet commercialized any product.
Does MANE pay dividends?
No, Veradermics does not pay a dividend. As a pre-revenue biopharmaceutical company, it directs its capital toward research and clinical development rather than shareholder distributions. Dividend payments are unlikely until the company reaches commercial-stage operations.
When does MANE report earnings?
Veradermics reports on a quarterly cadence standard for US-listed companies. Because it is pre-commercial, reports center on pipeline progress and cash position rather than revenue performance. Check the company's investor relations page for the current reporting schedule.
Is MANE a good stock to buy?
UQS Score rates MANE as Poor, with Weak readings across Quality, Moat, and Growth, and an Elevated Valuation. This profile reflects the high uncertainty typical of early-stage biopharma. Whether that risk-reward suits an individual investor depends on their own risk tolerance and portfolio context — not a recommendation either way.
Is MANE overvalued?
The UQS Valuation pillar for MANE is rated Elevated, suggesting the current market price may already reflect optimistic assumptions about pipeline success. For a company with no commercial revenue and Weak Quality and Growth scores, an Elevated Valuation warrants careful consideration.
How does MANE compare to its competitors?
Compared to peers like Tarsus Pharmaceuticals, which has a commercialized product, Veradermics remains entirely pre-revenue. Its differentiation lies in its dermatology-specific pipeline and microarray patch technology, though it carries the higher risk profile associated with earlier-stage development.
What is MANE's market cap bracket?
Veradermics is classified as a mid-cap company based on current market capitalization. This is relatively large for a clinical-stage biopharmaceutical company with no commercial products, which may partly explain the Elevated Valuation reading in the UQS Score framework.
Who founded Veradermics?
Veradermics was founded in 2019 and is headquartered in New Haven, Connecticut. For detailed information on the founding team and leadership, the company's official website and SEC filings are the most reliable sources.
Is MANE a long-term quality investment?
As a long-term quality indicator, the UQS Score rates MANE as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet established the durable business characteristics associated with long-term quality. Pipeline success could change this profile materially over time.
What is the main competitive advantage of Veradermics?
Veradermics' potential differentiation lies in its non-hormonal oral approach to pattern hair loss and its dissolvable microarray patch platform for immunotherapy. However, with a Weak Moat rating from UQS Score, these advantages are not yet considered durable or proven at a commercial scale.
Unlock Full MANE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar breakdowns for MANE
- ✓Access underlying financial metrics and trend data
- ✓Compare MANE side-by-side with dermatology and biopharma peers
- ✓Screen for higher-quality alternatives in the Healthcare sector
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
MANE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 8.7 | 0.0 | 6.0 | 0.0 | 48.1 | 0.0 | -1.2 |
| Apr 2, 2026 | 9.9 | 0.0 | 6.0 | 0.0 | 56.0 | 0.0 | — |
MANE — Pillar Breakdown
Quality
— 0.0/100 (25%)Veradermics, Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Veradermics, Incorporated faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 48.1/100 (15%)Veradermics, Incorporated has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Veradermics, Incorporated appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 6/100 (25%)Veradermics, Incorporated operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MANE.
Score Composition
Financial Data
More Stock Analysis
How is the MANE UQS Score Calculated?
The UQS (Unified Quality Score) for Veradermics, Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Veradermics, Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Veradermics, Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.